Ranbaxy Laboratories launches authorized generic Actos in US

NEW DELHI: Ranbaxy Laboratories has launched authorized pioglitazone hydrochloride tablets, generic version of Takeda's diabetes drug sold under the brand Actos in the US, a Ranbaxy release said.

The Indian company shares 180-day marketing exclusivity with Mylan and Teva. Ranbaxy could rake in $208 million and $63 million in sales and profit respectively, according to Fortune Equity Brokers.

The product is used to improve glycemic controls in adults with type 2 diabetes mellitus. The drug has total annual sales of $2.7 billion in the US, according to drug market research firm IMS Health data.

Bill Winter, VP, Trade Sales and Distribution, North America, Ranbaxy said, "Ranbaxy is making available the full range of generic pioglitazonein 15 mg, 30 mg, and 45 mg tablets."

Ranbaxy Laboratories' share price closed at Rs 515.05, up 0.94% at the BSE on Friday.